

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Rosen et al.

Application No.: Not Yet Assigned

Group Art Unit: N/A

Filed: February 01, 2002

Examiner: Not Yet Assigned

For: 25 HUMAN SECRETED PROTEINS

**PRELIMINARY AMENDMENT**

Commissioner for Patents  
Washington, DC 20231

Dear Sir:

Prior to the prosecution of the above-captioned application, please enter the following amendment:

**In the Specification:**

Please replace the first paragraph on page 1 with the following rewritten paragraph:

--This application is a continuation application of U.S. Application No. 09/781,417, filed February 13, 2001, which is a continuation-in-part of, and claims benefit under 35 U.S.C. § 120 to International Application Serial No. PCT/US00/22325, filed August 16, 2000, which is hereby incorporated by reference, which claims benefit under 35 U.S.C. § 119(e) based on U.S. Provisional Application No. 60/149,182, filed August 17, 1999, which is hereby incorporated by reference in its entirety.--

**In The Claims:**

Please enter the following amended claims 17 and 21:

17. (Amended) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11.

21. (Amended) The gene corresponding to the cDNA sequence of SEQ ID NO: X.

Please add the following claim:

24. (New) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polynucleotide of claim 1.

**REMARKS**

The specification has been amended to add priority information. The claims have been amended to more particularly point out and distinctly claim the subject matter Applicants regard as the invention. Support for new claim 24 can be found throughout the application as filed. Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "Version With Markings To Show Changes Made".

No new matter has been introduced.

Applicants believe that no fee is required for this submission. However, should a fee be due, please charge such fee to Deposit Account No. 08-3425. The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have

been filed herewith (or with any paper hereafter filed in this application by this firm) to our  
Deposit Account No. 08-3425, under Order No. PZ042P1C1.

Dated: February 01, 2002

Respectfully submitted,

By

Janet M. Martineau

Registration No.: 46,903

HUMAN GENOME SCIENCES, INC.

9410 Key West Avenue

Rockville, Maryland 20850

301 315-2723

Attorneys for Applicant

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Rosen et al.

Application No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Filed: February 01, 2002

Examiner: Not Yet Assigned

For: 25 HUMAN SECRETED PROTEINS

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

Amendments are shown in bold with insertions indicated with underlining and deletions indicated by strikeout.

**In the Specification:**

Please replace the first paragraph on page 1 with the following amended paragraph:

--This application is a **continuation application of U.S. Application No. 09/781,417, filed February 13, 2001, which is a** continuation-in-part of, and claims benefit under 35 U.S.C. § 120 ~~of~~**depending PCT to** International Application Serial No. PCT/US00/22325, filed August 16, 2000, which is hereby incorporated by reference, which claims benefit under 35 U.S.C. § 119(e) based on U.S. Provisional ~~Applications~~ **Application** No. 60/149,182, filed August 17, 1999, which is hereby incorporated by reference in its entirety.--

**In the Claims:**

Claim 17 and 21 have been amended as follows:

17. (Amended) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

21. (Amended) The gene corresponding to the cDNA sequence of SEQ ID NO: ~~Y~~X.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Rosen et al.

Application Number: to be assigned

Group Art Unit: to be assigned

Filed: herewith

Examiner: to be assigned

Title: 26 Human Secreted Proteins

Atty. Docket No. PZ042P1C1

**REQUEST UNDER 37 C.F.R. § 1.821(e)**

Commissioner for Patents  
Washington, D.C. 20231


Sir :

The above-identified patent application is a continuation of application Serial No. 09/781,417 filed February 13, 2001. The sequence listing of the instant application is identical to the sequence content of the computer readable sequence listing filed in connection with application Serial No. 09/781,417, on February 13, 2001.

In accordance with 37 C.F.R. § 1.821(e), please use the computer readable form filed in connection with application Serial No. 09/781,417 as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included in the specification of the instant application filed herewith. Applicants hereby certify that the paper copy of the Sequence Listing filed herewith and the computer readable sequence listing filed on February 13, 2001 in connection with application Serial No. 09/781,417 are the same and do not include new matter.

Respectfully submitted

Date: February 1, 2001

  
Janet M. Martineau (Reg. No. 46,903)  
Attorney for Applicants

Human Genome Sciences, Inc.  
9410 Key West Avenue  
Rockville, MD 20850  
(301) 315-2723 (telephone)

KKH/JMM/SA/vsr